课题基金 / 基金详情

A PILOT STUDY OF MUC1 VACCINE IN CURRENT AND FORMER SMOKERS AT HIGH RISK FOR LUNG CANCER

A PILOT STUDY OF MUC1 VACCINE IN CURRENT AND FORMER SMOKERS AT HIGH RISK FOR LUNG CANCER
MUC1 疫苗在当前和戒烟者肺癌高危人群中的试点研究
批准号:
9915603
负责人:
PAUL LIMBURG
金额:
$33.69万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2021-10-01

项目摘要

项目成果

PAUL LIMBURG的其他基金

相似基金

相关文献

中文摘要
翻译
拟定研究应评估MUC1疫苗在当前和既往肺癌高危吸烟者中的免疫原性和安全性。尽管之前评估了该疫苗构建体的安全性和免疫原性效果,在有结肠癌风险的个体中取得了令人鼓舞的结果,但对于有肺癌风险的个体,不能做出同样的假设。
英文摘要
The proposed study shall assess the immunogenicity and the safety of MUC1 vaccine in current and former smokers at high risk for lung cancer. Although safety and immunogenic effects of this vaccine construct were evaluated previously with promising results in individuals at risk for colon cancer the same cannot be assumed however for individuals at risk for lung cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE INFRASTRUCTURE SUPPORT FOR THE CANCER PREVENTION AGENT DEVELOPMENT PROGRAM
  • 批准号:
    10690408
  • 项目类别:
  • 资助金额:
    $5.42万
  • 财政年份:
    2019
  • 负责人:
    PAUL LIMBURG
  • 依托单位:
CORE INFRASTRUCTURE SUPPORT FOR THE CANCER PREVENTION AGENT DEVELOPMENT PROGRAM
  • 批准号:
    10045664
  • 项目类别:
  • 资助金额:
    $103.21万
  • 财政年份:
    2019
  • 负责人:
    PAUL LIMBURG
  • 依托单位:
CORE INFRASTRUCTURE SUPPORT FOR THE CANCER PREVENTION AGENT DEVELOPMENT PROGRAM
  • 批准号:
    10431751
  • 项目类别:
  • 资助金额:
    $51.26万
  • 财政年份:
    2019
  • 负责人:
    PAUL LIMBURG
  • 依托单位:
CORE INFRASTRUCTURE SUPPORT FOR THE CANCER PREVENTION AGENT DEVELOPMENT PROGRAM
  • 批准号:
    10249930
  • 项目类别:
  • 资助金额:
    $80.77万
  • 财政年份:
    2019
  • 负责人:
    PAUL LIMBURG
  • 依托单位:
海外基金